Allstate Corporation’s ImmunityBio IBRX Stock Holding History

Allstate Corporation’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$693K	Buy	79,201 +4,166	+6%	+$31.5K	0.01%	896
2026 Q1	$576K	Buy	+75,035	New	+$514K	0.01%	979

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Allstate Corporation's IBRX Position: Q2 2026 in Review

Allstate Corporation increased its ImmunityBio (IBRX) stake by 5.6% in Q2 2026, buying an estimated $31.5K and bringing the position to 79,201 shares worth $693K. The position accounts for 0.01% of the portfolio, ranked #896.

Allstate Corporation first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Allstate Corporation held 79,201 shares of ImmunityBio worth $693K as of Q2 2026.
Allstate Corporation bought 4,166 ImmunityBio shares in Q2 2026, an estimated $31.5K.
ImmunityBio made up 0.01% of Allstate Corporation's portfolio in Q2 2026, its #896 holding.
Allstate Corporation first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.